0001104659-21-151691.txt : 20211220 0001104659-21-151691.hdr.sgml : 20211220 20211220161108 ACCESSION NUMBER: 0001104659-21-151691 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20211219 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20211220 DATE AS OF CHANGE: 20211220 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Apollo Medical Holdings, Inc. CENTRAL INDEX KEY: 0001083446 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MANAGEMENT CONSULTING SERVICES [8742] IRS NUMBER: 870042699 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37392 FILM NUMBER: 211505361 BUSINESS ADDRESS: STREET 1: 1668 S. GARFIELD AVENUE STREET 2: 2ND FLOOR CITY: ALHAMBRA STATE: CA ZIP: 91801 BUSINESS PHONE: (626) 282-0288 MAIL ADDRESS: STREET 1: 1668 S. GARFIELD AVENUE STREET 2: 2ND FLOOR CITY: ALHAMBRA STATE: CA ZIP: 91801 FORMER COMPANY: FORMER CONFORMED NAME: SICLONE INDUSTRIES INC DATE OF NAME CHANGE: 19990413 8-K 1 tm2135903d1_8k.htm FORM 8-K
0001083446 false 0001083446 2021-12-20 2021-12-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): December 20, 2021 (December 19, 2021)

 

APOLLO MEDICAL HOLDINGS, INC.

(Exact Name of Registrant as Specified in Charter)

 

Delaware 001-37392 95-4472349
(State or Other Jurisdiction (Commission File (I.R.S. Employer
of Incorporation) Number) Identification No.)

 

1668 S. Garfield Avenue, 2nd Floor, Alhambra, California 91801

(Address of Principal Executive Offices) (Zip Code)

 

(626) 282-0288

Registrant’s Telephone Number, Including Area Code

 

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

  ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

  ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

  ¨ Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

  ¨ Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

  

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock AMEH Nasdaq Capital Market

 

 Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

 

Emerging growth company ¨

 

 If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.¨

 

 

   

 

 

Item 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On December 19, 2021, the Board of Directors (the “Board”) of Apollo Medical Holdings, Inc. (the “Company”) appointed Weili Dai and J. Lorraine Estradas, R.N., B.S.N., M.P.H. to serve as members of the Board, effective December 31, 2021.

 

Ms. Dai is the cofounder of global semiconductor company Marvell Technology where she served as president and director until 2016. In 2018, Ms. Dai cofounded MeetKai, Inc., an AI enabled personalized conversational search company, and continues to serve as its Executive Chairwoman today. She also serves as Chairman of the Board at Lark Technologies, Inc., a healthcare technology company aimed at delivering scalable, virtual chronic conditions care and preventative healthcare through conversational AI. Ms. Dai has been honored on Forbes’ “World’s Most Powerful Women” list and was named an EY Entrepreneur of the Year. Ms. Dai holds a B.S. in Computer Science from the University of California, Berkeley.

 

Ms. Estradas currently serves as the Chief Executive Officer of Arroyo Vista Family Health Center, a non-profit network of community health centers serving Greater Northeast Los Angeles since 1981. Under Ms. Estradas’ leadership, Arroyo Vista has grown from a small storefront clinic to a healthcare delivery network of four health centers and a mobile medical clinic serving the healthcare needs of medically underserved families within its local communities. Ms. Estradas also currently serves as a City Health Commissioner in Los Angeles. Her experience includes hospital and community public health nursing at UCLA, the Eastern Los Angeles Regional Center for the Developmentally Disabled, the State of California Department of Health Services – Rural Health Farmworker Division, and Arroyo Vista Family Health Center. Ms. Estradas has a Bachelor of Science degree in Nursing as well as a master’s degree in Public Health, both from UCLA.

 

There are no family relationships between Ms. Dai or Ms. Estradas and any director or executive officer of the Company. There are no arrangements or understandings between either Ms. Dai or Ms. Estradas and any other persons pursuant to which Ms. Dai and Ms. Estradas were appointed to the Board.

 

Arroyo Vista Family Health Center provides certain primary care services and other professional services to enrollees of certain health care service plans, the providers of which have contracted with Allied Physicians of California, a Professional Medical Corporation (“APC”), a consolidated variable interest entity of the Company. Under such arrangement, Arroyo Vista Family Health Center has paid Network Medical Management, Inc., the Company’s principal wholly-owned subsidiary, approximately $1.2 million for management and administrative services for the nine months ended September 30, 2021.

 

Ms. Dai is not a participant in, nor is she to be a participant in, any related-person transaction or proposed related-person transaction required to be disclosed by Item 404(a) of Regulation S-K under the Securities Exchange Act of 1934, as amended.

 

A copy of the press release containing the announcement of Ms. Dai and Ms. Estradas’ appointment is attached as Exhibit 99.1.

 

Item 9.01Financial Statements and Exhibits

 

(d) Exhibits.

 

Exhibit No.  Description
99.1  Press Release of Apollo Medical Holdings, Inc., dated December 20, 2021.
104  Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

APOLLO MEDICAL HOLDINGS, INC.
   
Date: December 20, 2021By:/s/ Thomas S. Lam
 Name:Thomas S. Lam, M.D., M.P.H.
 Title:Co-Chief Executive Officer and President

 

 

 EX-99.1 2 tm2135903d1_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1

 

 

Apollo Medical Holdings, Inc. Appoints Weili Dai and J. Lorraine Estradas to its Board of Directors

 

ALHAMBRA, Calif., December 20, 2021 /PRNewswire/ -- Apollo Medical Holdings, Inc. (“ApolloMed,” and together with its subsidiaries and affiliated entities, the “Company”) (NASDAQ: AMEH), a leading physician-centric, technology-powered healthcare company focused on enabling providers in the successful delivery of value-based care, today announced the appointments of Weili Dai, a renowned entrepreneur, technology executive and philanthropist, and J. Lorraine Estradas, R.N., B.S.N., M.P.H., an experienced leader in the Los Angeles healthcare industry, to its Board of Directors, effective December 31, 2021.

 

Boasting over 25 years of experience in the technology industry, Ms. Dai is the cofounder of global semiconductor company Marvell Technology where she served as President and Director until 2016. In 2018, Ms. Dai cofounded MeetKai, Inc., an AI-enabled personalized conversational search company, and continues to serve as its Executive Chairwoman today. She also serves as Chairman of the Board at Lark Health, a healthcare technology company aimed at delivering scalable, virtual chronic conditions care and preventive healthcare through conversational AI. Ms. Dai has been honored on Forbes’ “World’s Most Powerful Women” list and was named an EY Entrepreneur of the Year. She is recognized for her visionary work at Marvell and in technology advocacy for women and minorities. Ms. Dai holds a Bachelor of Science degree in Computer Science from the University of California, Berkeley.

 

Ms. Estradas currently serves as the Chief Executive Officer of Arroyo Vista Family Health Center, a non-profit network of community health centers serving Greater Northeast Los Angeles since 1981. Under Ms. Estradas’ leadership, Arroyo Vista has grown from a small storefront clinic to a healthcare delivery network of four health centers and a mobile medical clinic serving the healthcare needs of medically underserved families within its local communities as a Federally Qualified Health Center (FQHC). Ms. Estradas also currently serves as a City Health Commissioner in Los Angeles. Her experience includes hospital and community public health nursing at UCLA, the Eastern Los Angeles Regional Center for the Developmentally Disabled, the State of California Department of Health Services – Rural Health Farmworker Division, and Arroyo Vista Family Health Center. Ms. Estradas has a Bachelor of Science degree in Nursing as well as a master’s degree in Public Health, both from UCLA.

 

Brandon Sim, Co-Chief Executive Officer of ApolloMed, stated, “We are very excited to welcome Weili and Lorraine to the ApolloMed Board. We believe Weili’s extraordinary leadership and years of experience as an executive, venture capitalist, and board member in the technology and digital health industries will be a valuable asset to ApolloMed as we continue improving our technology platform and AI capabilities while executing on our nationwide growth strategy. Lorraine brings decades of knowledge and leadership within the Los Angeles healthcare community, as well as a proven ability to grow a community health organization and FQHC that is dedicated to providing the highest quality of compassionate, culturally sensitive care to a diverse community. We are thrilled to have tapped these two industry leaders as directors for our Board and look forward to benefitting from their guidance as we move forward with our plans to expand our model of empowering providers within our existing markets and beyond in the successful delivery of value-based care.”

 

 

 

 

About Apollo Medical Holdings, Inc.

 

ApolloMed is a leading physician-centric, technology-powered, risk-bearing healthcare company. Leveraging its proprietary end-to-end technology solutions, ApolloMed operates an integrated healthcare delivery platform that enables providers to successfully participate in value-based care arrangements, thus empowering them to deliver high quality care to patients in a cost-effective manner.

 

Headquartered in Alhambra, California, ApolloMed's subsidiaries and affiliates include management services organizations (MSOs), affiliated independent practice associations (IPAs), and a Next Generation Accountable Care Organization (NGACO). For more information, please visit www.apollomed.net.

 

Forward Looking Statements

 

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, such as statements about the Company’s operational focus, strategic growth and expansion plans, and future collaboration opportunities. Forward-looking statements reflect current views with respect to future events and financial performance and therefore cannot be guaranteed. Such statements are based on the current expectations and certain assumptions of ApolloMed’s management, and some or all of such expectations and assumptions may not materialize or may vary significantly from actual results. Actual results may also vary materially from forward-looking statements due to risks, uncertainties and other factors, known and unknown, including the risk factors described from time to time in ApolloMed’s reports filed with the Securities and Exchange Commission, including, without limitation, the risk factors contained in ApolloMed’s Annual Report on Form 10-K for the year ended December 31, 2020, and any subsequent Quarterly Reports on Form 10-Q.

 

FOR MORE INFORMATION, PLEASE CONTACT:

Investor Relations

(626) 943-6491

investors@apollomed.net

 

Carolyne Sohn, The Equity Group

(415) 568-2255

csohn@equityny.com

 

 

 EX-101.SCH 3 ameh-20211220.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 ameh-20211220_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 ameh-20211220_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm2135903d1_ex99-1img001.jpg GRAPHIC begin 644 tm2135903d1_ex99-1img001.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.21.4
Cover
Dec. 20, 2021
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Dec. 19, 2021
Entity File Number 001-37392
Entity Registrant Name APOLLO MEDICAL HOLDINGS, INC.
Entity Central Index Key 0001083446
Entity Tax Identification Number 95-4472349
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 1668 S. Garfield Avenue
Entity Address, Address Line Two 2nd Floor
Entity Address, City or Town Alhambra
Entity Address, State or Province CA
Entity Address, Postal Zip Code 91801
City Area Code 626
Local Phone Number 282-0288
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol AMEH
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 tm2135903d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001083446 2021-12-20 2021-12-20 iso4217:USD shares iso4217:USD shares 0001083446 false 8-K 2021-12-19 APOLLO MEDICAL HOLDINGS, INC. DE 001-37392 95-4472349 1668 S. Garfield Avenue 2nd Floor Alhambra CA 91801 626 282-0288 false false false false Common Stock AMEH NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.4 html 1 118 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://apollomed.net/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2135903d1_8k.htm ameh-20211220.xsd ameh-20211220_lab.xml ameh-20211220_pre.xml tm2135903d1_ex99-1.htm http://xbrl.sec.gov/dei/2020-01-31 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2135903d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "tm2135903d1_8k.htm" ] }, "labelLink": { "local": [ "ameh-20211220_lab.xml" ] }, "presentationLink": { "local": [ "ameh-20211220_pre.xml" ] }, "schema": { "local": [ "ameh-20211220.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 118, "memberCustom": 0, "memberStandard": 0, "nsprefix": "AMEH", "nsuri": "http://apollomed.net/20211220", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2135903d1_8k.htm", "contextRef": "From2021-12-20to2021-12-20", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://apollomed.net/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2135903d1_8k.htm", "contextRef": "From2021-12-20to2021-12-20", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r9", "r11", "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://apollomed.net/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r11": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r12": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r13": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r14": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r15": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r16": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r17": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r18": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" } }, "version": "2.1" } ZIP 15 0001104659-21-151691-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-21-151691-xbrl.zip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end